Literature DB >> 14594958

Treatment for newly diagnosed hypertension: patterns of prescribing and antihypertensive effectiveness in the UK.

Tom Walley1, Andy K Duggan, Alan R Haycox, Christie J Niziol.   

Abstract

Improved practice in the management of hypertension depends on an understanding of existing patterns of treatment. To describe the management of newly diagnosed hypertension in British general practice and the effectiveness of current prescribing patterns we conducted a retrospective observational study using data from a computerized general practitioner record database (DIN-LINK). 21 024 patients were first treated for newly diagnosed hypertension between January 1993 and December 1997, and were followed for 4 years. Diuretics or beta-blockers were the most widely prescribed first-line treatments, used in 54% of patients. The mean continuation rate for first-line therapy was 69% at 12 months: the continuation rate was highest for angiotensin converting enzyme inhibitors/angiotensin II receptor antagonists. After 12 months of treatment the mean blood pressure reduction was 19/10 mmHg. Blood pressure targets were met in only 14% of patients. After 48 months of treatment 34% of patients had not improved in band of blood pressure severity. Many patients with severe hypertension at 12 months were still being prescribed only one drug. The lack of aggression in antihypertensive treatment, indicated by the low number of agents prescribed and the failure to achieve targets, is disappointing. Prescribing patterns for first-line therapy corresponded to guidelines. Continuation rates on first-line therapy were higher than often reported. The choice of drug for additions to or switches from first-line therapy had no clear pattern. Routinely collected computerized data could be used to support clinical governance activities in primary care.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14594958      PMCID: PMC539623          DOI: 10.1177/014107680309601104

Source DB:  PubMed          Journal:  J R Soc Med        ISSN: 0141-0768            Impact factor:   18.000


  25 in total

1.  Adverse drug reactions in current antihypertensive therapy: a general practice survey of 2586 patients in Norway.

Authors:  H Olsen; T Klemetsrud; H P Stokke; S Tretli; A Westheim
Journal:  Blood Press       Date:  1999       Impact factor: 2.835

2.  Initial treatment choices, second-line therapy, and reasons for stopping medication in the treatment of hypertension by general practitioners in England, Scotland and Wales: 1990-1995.

Authors:  R M Martin; S M Kerry; S R Hilton
Journal:  Pharmacoepidemiol Drug Saf       Date:  1997-07       Impact factor: 2.890

3.  Pharmacoutilization of antihypertensive drugs: a model of analysis.

Authors:  E Degli Esposti; A Sturani; L Degli Esposti; P L Macini; P Falasca; G Valpiani; S Buda
Journal:  Int J Clin Pharmacol Ther       Date:  2001-06       Impact factor: 1.366

4.  Effect of initial drug choice on persistence with antihypertensive therapy: the importance of actual practice data.

Authors:  J J Caro; J L Speckman; M Salas; G Raggio; J D Jackson
Journal:  CMAJ       Date:  1999-01-12       Impact factor: 8.262

5.  Optimisation of antihypertensive treatment by crossover rotation of four major classes.

Authors:  J E Dickerson; A D Hingorani; M J Ashby; C R Palmer; M J Brown
Journal:  Lancet       Date:  1999-06-12       Impact factor: 79.321

Review 6.  Guidelines for management of hypertension: report of the third working party of the British Hypertension Society.

Authors:  L Ramsay; B Williams; G Johnston; G MacGregor; L Poston; J Potter; N Poulter; G Russell
Journal:  J Hum Hypertens       Date:  1999-09       Impact factor: 3.012

7.  Management guidelines in essential hypertension: report of the second working party of the British Hypertension Society.

Authors:  P Sever; G Beevers; C Bulpitt; A Lever; L Ramsay; J Reid; J Swales
Journal:  BMJ       Date:  1993-04-10

Review 8.  Auditing the management of hypertension in British general practice: a critical literature review.

Authors:  M Cranney; S Barton; T Walley
Journal:  Br J Gen Pract       Date:  1998-07       Impact factor: 5.386

9.  Hypertension guidelines in elderly patients: is anybody listening?

Authors:  Karen Tu; Muhammad M Mamdani; Jack V Tu
Journal:  Am J Med       Date:  2002-07       Impact factor: 4.965

10.  Blood pressure screening, management and control in England: results from the health survey for England 1994.

Authors:  H M Colhoun; W Dong; N R Poulter
Journal:  J Hypertens       Date:  1998-06       Impact factor: 4.844

View more
  22 in total

1.  Oversight: a retrospective study of biochemical monitoring in patients beginning antihypertensive drug treatment in primary care.

Authors:  Jamie J Coleman; Sarah E McDowell; Stephen J W Evans; Paramjit S Gill; Robin E Ferner
Journal:  Br J Clin Pharmacol       Date:  2010-07       Impact factor: 4.335

2.  How much monitoring?

Authors:  Paul Glasziou
Journal:  Br J Gen Pract       Date:  2007-05       Impact factor: 5.386

3.  Prescribing pattern of antihypertensive drugs in primary care units in Turkey: results from the TURKSAHA study.

Authors:  Adnan Abaci; Omer Kozan; Aytekin Oguz; Mahmut Sahin; Necmi Deger; Huseyin Senocak; Nizamettin Toprak; Haydar Sur; Cetin Erol
Journal:  Eur J Clin Pharmacol       Date:  2007-04       Impact factor: 2.953

4.  Benefit of initial dual-therapy on stroke prevention in Chinese hypertensive patients: a real world cohort study.

Authors:  Jin-Ming Yu; Qun-Yu Kong; Tian Shen; Yu-Song He; Ji-Wei Wang; Yan-Ping Zhao
Journal:  J Thorac Dis       Date:  2015-05       Impact factor: 2.895

5.  Individuals at risk of beta-blocker discontinuation: a cohort study in 19,177 Chinese patients.

Authors:  Martin C S Wong; Johnny Y Jiang; Xuefen Su; Haoxiang Wang; Jin Ling Tang; Sian M Griffiths
Journal:  Clin Res Cardiol       Date:  2010-02-21       Impact factor: 5.460

6.  Potential population impact of the UK government strategy for reducing the burden of coronary heart disease in England: comparing primary and secondary prevention strategies.

Authors:  I Gemmell; R F Heller; K Payne; R Edwards; M Roland; P Durrington
Journal:  Qual Saf Health Care       Date:  2006-10

Review 7.  Choice of first antihypertensive--are existing guidelines ignored?

Authors:  Ifeanyi Okechukwu; Azra Mahmud; Kathleen Bennett; John Feely
Journal:  Br J Clin Pharmacol       Date:  2007-10-22       Impact factor: 4.335

8.  Utilisation of angiotensin receptor blockers in Sweden: combining survey and register data to study adherence to prescribing guidelines.

Authors:  Pia Frisk; Tor-Olov Mellgren; Niklas Hedberg; Anita Berlin; Fredrik Granath; Björn Wettermark
Journal:  Eur J Clin Pharmacol       Date:  2008-08-15       Impact factor: 2.953

9.  Hypertension guideline recommendations in general practice: awareness, agreement, adoption, and adherence.

Authors:  Carl Heneghan; Rafael Perera; David Mant; Paul Glasziou
Journal:  Br J Gen Pract       Date:  2007-12       Impact factor: 5.386

10.  Patients With Newly Diagnosed Hypertension Treated With the Renin Angiotensin Receptor Blocker Azilsartan Medoxomil vs Angiotensin-Converting Enzyme Inhibitors: The Prospective EARLY Registry.

Authors:  Roland E Schmieder; Sebastian A Potthoff; Peter Bramlage; Peter Baumgart; Felix Mahfoud; Hartmut Buhck; Taoufik Ouarrak; Martina Ehmen; Jochen Senges; Anselm K Gitt
Journal:  J Clin Hypertens (Greenwich)       Date:  2015-06-24       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.